$FATE
Fate Therapeutics Inc

2017 Q1 Form 10-Q Financial Statement

#000156459017011043 Filed on May 15, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $1.027M $1.322M
YoY Change -22.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.030M $2.600M
YoY Change 16.54% -5.8%
% of Gross Profit
Research & Development $7.970M $6.636M
YoY Change 20.1% 45.27%
% of Gross Profit
Depreciation & Amortization $206.0K $227.0K
YoY Change -9.25% 77.34%
% of Gross Profit
Operating Expenses $11.00M $9.238M
YoY Change 19.05% 26.13%
Operating Profit -$7.916M
YoY Change 8.08%
Interest Expense -$160.0K $488.0K
YoY Change -132.79% -12.54%
% of Operating Profit
Other Income/Expense, Net -$461.0K
YoY Change -17.24%
Pretax Income -$10.13M -$8.380M
YoY Change 20.88% 6.35%
Income Tax
% Of Pretax Income
Net Earnings -$10.13M -$8.377M
YoY Change 20.88% 6.29%
Net Earnings / Revenue -985.98% -633.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$244.7K -$291.2K
COMMON SHARES
Basic Shares Outstanding 41.39M 28.86M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.30M $55.60M
YoY Change 48.02% 31.44%
Cash & Equivalents $40.73M $39.49M
Short-Term Investments $41.70M $16.10M
Other Short-Term Assets $1.100M $1.000M
YoY Change 10.0% 150.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $83.40M $56.60M
YoY Change 47.35% 32.24%
LONG-TERM ASSETS
Property, Plant & Equipment $1.700M $2.000M
YoY Change -15.0% 33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K
YoY Change 0.0% -50.0%
Total Long-Term Assets $1.900M $2.100M
YoY Change -9.52% 23.53%
TOTAL ASSETS
Total Short-Term Assets $83.40M $56.60M
Total Long-Term Assets $1.900M $2.100M
Total Assets $85.30M $58.70M
YoY Change 45.32% 31.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.500M $2.000M
YoY Change 25.0% 53.85%
Accrued Expenses $4.700M $2.000M
YoY Change 135.0% 11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.620M $7.700M
YoY Change -1.04% 133.33%
Total Short-Term Liabilities $16.90M $13.90M
YoY Change 21.56% 117.19%
LONG-TERM LIABILITIES
Long-Term Debt $1.100M $8.700M
YoY Change -87.36% -46.95%
Other Long-Term Liabilities $3.500M $5.400M
YoY Change -35.19% 1250.0%
Total Long-Term Liabilities $4.600M $14.10M
YoY Change -67.38% -16.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.90M $13.90M
Total Long-Term Liabilities $4.600M $14.10M
Total Liabilities $21.50M $28.00M
YoY Change -23.21% 20.69%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.86M $30.70M
YoY Change
Total Liabilities & Shareholders Equity $85.30M $58.70M
YoY Change 45.32% 31.91%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$10.13M -$8.377M
YoY Change 20.88% 6.29%
Depreciation, Depletion And Amortization $206.0K $227.0K
YoY Change -9.25% 77.34%
Cash From Operating Activities -$7.460M -$7.250M
YoY Change 2.9% 13.64%
INVESTING ACTIVITIES
Capital Expenditures $155.0K $178.0K
YoY Change -12.92% -60.62%
Acquisitions
YoY Change
Other Investing Activities -$38.22M -$16.17M
YoY Change 136.36%
Cash From Investing Activities -$38.38M -$16.34M
YoY Change 134.88% 3531.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $2.011M $1.873M
YoY Change 7.37%
Cash From Financing Activities -2.170M -1.730M
YoY Change 25.43% -2262.5%
NET CHANGE
Cash From Operating Activities -7.460M -7.250M
Cash From Investing Activities -38.38M -16.34M
Cash From Financing Activities -2.170M -1.730M
Net Change In Cash -48.01M -25.32M
YoY Change 89.61% 275.11%
FREE CASH FLOW
Cash From Operating Activities -$7.460M -$7.250M
Capital Expenditures $155.0K $178.0K
Free Cash Flow -$7.615M -$7.428M
YoY Change 2.52% 8.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
40000
CY2017Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1000
CY2016Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-55000
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
77000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-75000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1677000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7455000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
155000
CY2017Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
39971000
CY2016Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
16166000
CY2017Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
1750000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-38376000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16344000
CY2017Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
34000
CY2016Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
147000
CY2017Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2011000
CY2016Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1873000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2170000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1726000
CY2017Q1 us-gaap Short Term Investments
ShortTermInvestments
41692000
CY2017Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
7620000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
248957000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2303000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16897000
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
543000
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
249820000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
790000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
112000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7252000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2602000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
9238000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7916000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2016Q1 us-gaap Interest Expense
InterestExpense
488000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-461000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8377000
CY2017Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-33000
CY2016Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10159000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8363000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41388329
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28777790
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
206000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
227000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
867000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
797000
CY2017Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
24000
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
157000
CY2017Q1 us-gaap Straight Line Rent
StraightLineRent
-272000
CY2016Q1 us-gaap Straight Line Rent
StraightLineRent
7000
CY2017Q1 fate Deferred Revenue Expense
DeferredRevenueExpense
526000
CY2016Q1 fate Deferred Revenue Expense
DeferredRevenueExpense
822000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
178000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
3504000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
3503000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1409000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10765000
CY2016Q4 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
7000
CY2016Q4 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
10758000
CY2016Q4 fate Long Term Debt Gross Current
LongTermDebtGrossCurrent
8257000
CY2017Q1 fate Debt Instrument Discount Current
DebtInstrumentDiscountCurrent
51000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-48001000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-25322000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64809000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39487000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p></div>
CY2017Q1 us-gaap Revenue Recognition Milestone Method Factors
RevenueRecognitionMilestoneMethodFactors
(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured.
CY2017Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20200000
CY2017Q1 fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
6000000
CY2016Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4500000
CY2016Q1 fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
4400000
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41726000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
34000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
41692000
CY2017Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1041000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1505000
CY2017Q1 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1205000
CY2016Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1043000
CY2017Q1 fate Accrued Final Payment Fee On Debt Current
AccruedFinalPaymentFeeOnDebtCurrent
705000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1748000
CY2017Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8753000
CY2017Q1 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
1000
CY2017Q1 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
8752000
CY2017Q1 fate Long Term Debt Gross Current
LongTermDebtGrossCurrent
7671000
CY2016Q4 fate Debt Instrument Discount Current
DebtInstrumentDiscountCurrent
70000
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
300000
CY2016Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
500000
CY2016Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
100000

Files In Submission

Name View Source Status
0001564590-17-011043-index-headers.html Edgar Link pending
0001564590-17-011043-index.html Edgar Link pending
0001564590-17-011043.txt Edgar Link pending
0001564590-17-011043-xbrl.zip Edgar Link pending
fate-10q_20170331.htm Edgar Link pending
fate-20170331.xml Edgar Link completed
fate-20170331.xsd Edgar Link pending
fate-20170331_cal.xml Edgar Link unprocessable
fate-20170331_def.xml Edgar Link unprocessable
fate-20170331_lab.xml Edgar Link unprocessable
fate-20170331_pre.xml Edgar Link unprocessable
fate-ex311_7.htm Edgar Link pending
fate-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending